CRP and neoplasm: CRT did not completely suppress tumor viability and tumor-derived inflammation in patients with persistent inflammation (i.e., elevated CRP levels) after CRT, because they relapsed earlier after durvalumab consolidation than those with improved inflammation (Figure 3A,B).